Apotex Secures FDA Approval for Infuvite Pediatric Injection

WESTON, FLORIDA, April 27, 2026

Apotex has secured U.S. Food and Drug Administration (FDA) approval for its generic Infuvite® Pediatric Injection, marking a significant milestone in expanding access to parenteral nutrition therapies for pediatric patients. The approval, granted under an Abbreviated New Drug Application (ANDA), also confers 180-day Competitive Generic Therapy (CGT) exclusivity for the single-dose vial formulation, positioning Apotex as a key player in the injectable generics market. This development follows closely on the heels of the company’s recent FDA approval for generic Infuvite® Adult Injection, demonstrating a coordinated strategy to address both adult and pediatric nutritional needs.

FDA Approval Strengthens Generic Injectable Portfolio

The FDA authorization of generic Infuvite® Pediatric Injection underscores Apotex’s expanding leadership in sterile injectable generics, a segment characterized by high regulatory scrutiny, complex manufacturing requirements, and critical patient applications. The product is designed to deliver essential vitamins through intravenous administration, supporting patients who require parenteral nutrition due to inability to receive adequate nutrients orally or enterally.

The 180-day CGT exclusivity provides Apotex with a competitive advantage in the U.S. market, enabling a temporary period of limited competition while improving access to affordable therapies. This regulatory incentive is particularly significant in the generics space, where market entry timing and exclusivity windows play a crucial role in commercial success.

By securing approvals for both pediatric and adult formulations within a short timeframe, Apotex demonstrates strong regulatory execution and portfolio alignment, ensuring comprehensive coverage across patient populations. This dual approval strategy enhances supply continuity and strengthens the company’s presence in hospital and clinical care settings.

Advanced Manufacturing and Regulatory Excellence

The successful approval reflects a collaborative effort between Apotex, Orbicular Pharmaceutical Technologies, and Gland Pharma Limited, combining expertise in formulation development, analytical characterization, and sterile injectable manufacturing. The development process required highly specialized capabilities to ensure product stability, sterility, and regulatory compliance, all of which are critical for injectable products used in vulnerable patient populations.

Sterile injectable manufacturing remains one of the most complex areas in pharmaceutical production, requiring strict adherence to current Good Manufacturing Practices (cGMP), advanced quality control systems, and robust validation processes. The approval highlights the partners’ ability to meet these stringent requirements while delivering a product that meets FDA standards for safety, efficacy, and quality equivalence.

Gland Pharma’s extensive experience in injectable manufacturing and Orbicular’s expertise in complex generics development played a pivotal role in achieving regulatory success, reinforcing the importance of strategic partnerships in navigating the challenges of global pharmaceutical development.

Expanding Access to Essential Nutrition Therapies

Parenteral nutrition products such as Infuvite® are essential for patients who cannot meet their nutritional needs through conventional means, including those with gastrointestinal disorders, critical illnesses, or post-surgical recovery requirements. The availability of generic pediatric formulations is particularly important, as it ensures that younger patients have access to safe, effective, and affordable nutritional support.

This approval aligns with broader healthcare goals of improving access to essential medicines while reducing treatment costs, especially in hospital settings where injectable therapies are widely used. By introducing a cost-effective generic alternative, Apotex contributes to enhancing healthcare system sustainability and patient outcomes.

From a cGxP perspective, the approval highlights the critical role of regulatory compliance, manufacturing excellence, and quality assurance in delivering safe injectable products, emphasizing the importance of maintaining rigorous standards throughout the product lifecycle. The achievement also reflects the growing importance of generic pharmaceuticals in addressing global healthcare needs, particularly in high-demand therapeutic areas such as nutrition and critical care.

Source: Apotex press release